DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Increased by Bessemer Group Inc.

Bessemer Group Inc. grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 949,091 shares of the medical device company's stock after acquiring an additional 25,459 shares during the quarter. Bessemer Group Inc. owned about 0.24% of DexCom worth $64,812,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Private Trust Co. NA raised its holdings in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the period. Optiver Holding B.V. acquired a new stake in shares of DexCom in the fourth quarter worth $33,000. TD Private Client Wealth LLC increased its position in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC raised its stake in shares of DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the 4th quarter valued at $38,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now owns 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $83.13, for a total transaction of $228,607.50. Following the completion of the sale, the director now owns 56,621 shares in the company, valued at approximately $4,706,903.73. This represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 25,724 shares of company stock valued at $2,157,034. Insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Citigroup reiterated a "buy" rating and issued a $102.00 target price (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Truist Financial assumed coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target on the stock. Canaccord Genuity Group upped their price target on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st. Four investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $98.50.

DexCom Stock Performance

DXCM traded up $1.29 during trading hours on Friday, hitting $86.33. 4,632,374 shares of the stock were exchanged, compared to its average volume of 4,393,450. The stock has a market cap of $33.85 billion, a price-to-earnings ratio of 64.43, a price-to-earnings-growth ratio of 1.81 and a beta of 1.46. The stock has a 50-day simple moving average of $81.34 and a 200-day simple moving average of $79.54. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a return on equity of 30.05% and a net margin of 12.90%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the previous year, the business posted $0.32 earnings per share. The company's quarterly revenue was up 12.5% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.